Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
56
-
Total 13F shares, excl. options
-
60.8M
-
Shares change
-
+2.94M
-
Total reported value, excl. options
-
$1.2B
-
Value change
-
+$60.2M
-
Number of buys
-
42
-
Number of sells
-
-21
-
Price
-
$19.69
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q1 2018
70 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q1 2018.
Denali Therapeutics Inc. - Common Stock (DNLI) has 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60.8M shares
of 145M outstanding shares and own 41.88% of the company stock.
Largest 10 shareholders include Crestline Management, LP (20.6M shares), FMR LLC (9.54M shares), Flagship Pioneering Inc. (8.92M shares), BAILLIE GIFFORD & CO (5.19M shares), Temasek Holdings (Private) Ltd (4.41M shares), FIL Ltd (4.18M shares), VANGUARD GROUP INC (1.13M shares), BlackRock Inc. (1.05M shares), BAMCO INC /NY/ (914K shares), and Alphabet Inc. (567K shares).
This table shows the top 56 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.